Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform
Parabilis Medicines Q2 EPS $(2.32) Misses $(0.08) Estimate, Sales $148.000K Miss $25.000M Estimate
Leerink Partners Initiates Coverage On Parabilis Medicines with Outperform Rating, Announces Price Target of $40
B of A Securities Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $45
Parabilis Medicines (PBLS) Stock Valuation After Recent 10% Single Day Decline
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Parabilis Medicines Announces Pricing of Upsized Initial Public Offering
Parabilis Medicines Starts IPO On Promising Cancer Therapy Trials
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
